Sphingotec to Launch Protein Markers for Breast Cancer Risk in US This Year | GenomeWeb

NEW YORK (GenomeWeb) – German biomarker firm Sphingotec plans this year to launch its protein-based test for breast cancer risk prediction in the US.

The company will offer the test, which measures levels of the proteins proneurotensin (pro-NT) and proenkephalin (pro-ENK) to predict medium-term breast cancer risk in healthy women, through clinical reference lab Innovative Diagnostic Laboratory beginning in December, Karla Gonye, president of the company's US subsidiary, told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.